Moderna IPO On Path To Be Largest Offering Of Venture-Backed Biotech [Investor's Business Daily]
Vertex Pharmaceuticals Incorporated (VRTX)
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.vrtx.com
Company Research
Source: Investors Business Daily
Related news Moderna Therapeutics ( MRNA ) is set to become the largest initial public offering of a venture capital-backed biotech company, setting IPO terms that could raise $521 million. X The company develops drugs for the treatment of infectious diseases, genetic disorders, cancer and cardiovascular diseases, by using messenger RNA technology to convey genetic information within cells. Moderna says its mission is to create "a new generation of transformative medicines for patients," according to the Moderna IPO prospectus . It has a pipeline of 21 development programs, of which 10 have entered clinical studies. The Moderna IPO plans to offer 21.7 million shares priced in the range of $22 to $24. That gives it a market valuation near $8 billion. At the high end of that range, Moderna would raise $521 million. The company has received about $1.6 billion in venture funding, including $125 million in May from the venture capital unit of Merck ( MRK ). In addition to Merck,
Show less
Read more
Impact Snapshot
Event Time:
VRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRTX alerts
High impacting Vertex Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
VRTX
News
- Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain [Yahoo! Finance]Yahoo! Finance
- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target lowered by analysts at UBS Group AG from $498.00 to $466.00. They now have a "buy" rating on the stock.MarketBeat
- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Guggenheim from $445.00 to $450.00. They now have a "buy" rating on the stock.MarketBeat
- Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic PainBusiness Wire
- Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know [Yahoo! Finance]Yahoo! Finance
VRTX
Earnings
- 2/5/24 - Beat
VRTX
Sec Filings
- 4/17/24 - Form 4
- 4/16/24 - Form PX14A6G
- 4/11/24 - Form SC
- VRTX's page on the SEC website